Harald Polzer
Munich, BY, Germany
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 10 publications
A series of novel aryl-methanone derivatives as inhibitors of FMS-like tyrosine kinase 3 (FLT3) in FLT3-ITD-positive acute myeloid leukemia.
Journal: European journal of medicinal chemistry
Published: November 04, 2019
The target landscape of clinical kinase drugs.
Journal: Science (New York, N.Y.)
Published: April 13, 2017
Tyrosine kinase inhibition increases the cell surface localization of FLT3-ITD and enhances FLT3-directed immunotherapy of acute myeloid leukemia.
Journal: Leukemia
Published: April 07, 2017
The new and recurrent FLT3 juxtamembrane deletion mutation shows a dominant negative effect on the wild-type FLT3 receptor.
Journal: Scientific reports
Published: January 12, 2016
Microenvironmental hypoxia regulates FLT3 expression and biology in AML.
Journal: Scientific reports
Published: August 18, 2015
Activating FLT3 mutants show distinct gain-of-function phenotypes in vitro and a characteristic signaling pathway profile associated with prognosis in acute myeloid leukemia.
Journal: PloS one
Published: September 14, 2013
Exome sequencing identifies recurring FLT3 N676K mutations in core-binding factor leukemia.
Journal: Blood
Published: July 24, 2013
Breakdown of the FLT3-ITD/STAT5 axis and synergistic apoptosis induction by the histone deacetylase inhibitor panobinostat and FLT3-specific inhibitors.
Journal: Molecular cancer therapeutics
Published: September 04, 2012
Casitas B-lineage lymphoma mutants activate AKT to induce transformation in cooperation with class III receptor tyrosine kinases.
Journal: Experimental hematology
Published: August 30, 2012
Showing 1-10 of 10
Last Updated: 09/26/2026